Merck & Co., Inc. (MRK) Evercore eighth Annual Healthcare Convention December 2, 2025 9:10 AM EST
Firm Members
Eliav Barr – Chief Medical Officer & Head of World Medical Growth of Merck Analysis Laboratories
Chirfi Guindo – Senior VP & Chief Advertising and marketing Officer of Human Well being
Peter Dannenbaum – Vice President of Investor Relations
Convention Name Members
Umer Raffat – Evercore ISI Institutional Equities, Analysis Division
Presentation
Umer Raffat
Evercore ISI Institutional Equities, Analysis Division
All proper. Incredible. So we’ll leap proper in. I wish to do R&D and business. Do we’ve got a desire the place we should always begin? Okay. We’ll begin possibly somewhat bit on the R&D facet, and we’ll come again to business, then most likely return into R&D once more.
Possibly in no specific order, let me begin with the CADENCE trial, clear success. However it seems to be like for — there was these questions round whether or not it was sufficient to warrant an FDA submission or a minimum of a regulatory dialog. It does not seem like it met that bar. Was there a sure quantity you guys had been anticipating or sure endpoints that will have warranted that? How ought to we take into consideration that?
Eliav Barr
Chief Medical Officer & Head of World Medical Growth of Merck Analysis Laboratories
Sure. So we’re very excited in regards to the CADENCE outcomes as a result of these are sufferers that do not have any doable — any present remedy to enhance their outcomes and their potential to have interaction in actions of each day dwelling. These are sufferers who’ve received pre- and post-capillary pulmonary hypertension attributable to coronary heart failure with preserved ejection fraction. So it is a actually discrete however essential inhabitants. And the outcomes had been actually fairly good. We’re very proud of them.
This was a proof-of-concept research. So it isn’t a regulatory — it isn’t a submitting research, however it gave us rock-solid
